Article info
PDFCorrespondence response
Response to: ‘Correspondence on: ‘Dupilumab as a novel steroid-sparing treatment for IgG4-related disease’ by Simpson et al’ by Ebbo et al
- Correspondence to Rachel S Simpson, Toronto Allergists, Toronto, Ontario, Canada; rachel.simpson{at}queensu.ca
Citation
Response to: ‘Correspondence on: ‘Dupilumab as a novel steroid-sparing treatment for IgG4-related disease’ by Simpson et al’ by Ebbo et al
Publication history
- Received February 19, 2020
- Accepted February 20, 2020
- First published March 10, 2020.
Online issue publication
January 12, 2022
Article Versions
- Previous version (10 March 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.